Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

1.

Individual tumor response testing in multiple relapsed acute myeloid leukemia in children.

Styczynski J, Piatkowska M, Czyzewski K, Pogorzala M, Wysocki M.

Anticancer Res. 2013 Mar;33(3):1189-93.

PMID:
23482801
[PubMed - indexed for MEDLINE]
2.

Ex vivo drug resistance profile in childhood acute myelogenous leukemia: no drug is more effective in comparison to acute lymphoblastic leukemia.

Styczynski J, Wysocki M, Debski R, Juraszewska E, Malinowska I, Stanczak E, Ploszynska A, Stefaniak J, Mazur B, Szczepanski T.

Leuk Lymphoma. 2002 Sep;43(9):1843-8.

PMID:
12685842
[PubMed - indexed for MEDLINE]
3.

Ex vivo drug resistance in childhood acute myeloid leukemia on relapse is not higher than at first diagnosis.

Styczynski J, Wysocki M.

Pediatr Blood Cancer. 2004 Feb;42(2):195-9.

PMID:
14752887
[PubMed - indexed for MEDLINE]
4.

In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses.

Styczynski J, Wysocki M, Debski R, Czyzewski K, Balwierz W, Juraszewska E, Matysiak M, Malinowska I, Stanczak E, Sońta-Jakimczyk D, Szczepanski T, Wachowiak J, Konatkowska B, Balcerska A, Ploszynska A, Kowalczyk J, Stefaniak J, Badowska W, Wieczorek M, Olejnik I, Krawczuk-Rybak M, Kuzmicz M.

Neoplasma. 2005;52(1):74-8.

PMID:
15739031
[PubMed - indexed for MEDLINE]
5.

Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.

Zwaan CM, Kaspers GJ, Pieters R, Hählen K, Janka-Schaub GE, van Zantwijk CH, Huismans DR, de Vries E, Rots MG, Peters GJ, Jansen G, Creutzig U, Veerman AJ.

Blood. 2002 Jan 1;99(1):245-51.

PMID:
11756178
[PubMed - indexed for MEDLINE]
Free Article
6.

Individualized tumor response testing profile has a prognostic value in childhood acute leukemias: multicenter non-interventional long-term follow-up study.

Piatkowska M, Styczynski J, Kolodziej B, Kurylo-Rafinska B, Kubicka M, Pogorzala M, Czyzewski K, Debski R, Matysiak M, Malinowska I, Balwierz W, Juraszewska E, Wachowiak J, Konatkowska B, Wieczorek M, Olejnik I, Krawczuk-Rybak M, Kuzmicz M, Kowalczyk J, Stefaniak MJ, Badowska W, Szczepanski T, Tomaszewska R, Adamkiewicz-Drozynska E, Maciejka-Kapuscinska L, Sobol G, Mizia-Malarz A, Wysocki M.

Leuk Lymphoma. 2013 Jun;54(6):1256-62. doi: 10.3109/10428194.2012.741231. Epub 2012 Nov 21.

PMID:
23088710
[PubMed - indexed for MEDLINE]
7.

Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia.

Styczynski J, Wysocki M, Dluzniewska A, Juraszewska E, Balwierz W, Czyzewski K, Wieczorek M, Olejnik I, Krawczuk-Rybak M, Kuzmicz M, Kowalczyk J, Stefaniak J, Badowska W, Sonta-Jakimczyk D, Szczepanski T, Matysiak M, Stanczak E, Malinowska I, Wachowiak J, Konatkowska B, Gil L, Balcerska A, Kapuscinska L, Szczepanek J, Kolodziej B, Rafinska B, Kubicka M.

Anticancer Res. 2008 May-Jun;28(3B):1927-31.

PMID:
18630483
[PubMed - indexed for MEDLINE]
Free Article
8.

Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities.

Zwaan CM, Kaspers GJ, Pieters R, Hählen K, Huismans DR, Zimmermann M, Harbott J, Slater RM, Creutzig U, Veerman AJ.

Blood. 2002 Nov 1;100(9):3352-60.

PMID:
12384437
[PubMed - indexed for MEDLINE]
Free Article
9.

Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia.

Zwaan CM, Kaspers GJ, Pieters R, Ramakers-Van Woerden NL, den Boer ML, Wünsche R, Rottier MM, Hählen K, van Wering ER, Janka-Schaub GE, Creutzig U, Veerman AJ.

Blood. 2000 Oct 15;96(8):2879-86.

PMID:
11023525
[PubMed - indexed for MEDLINE]
Free Article
10.

[IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].

Fleischhack G, Graf N, Hasan C, Ackermann M, Breu H, Zernikow B, Bode U.

Klin Padiatr. 1996 Jul-Aug;208(4):229-35. German.

PMID:
8926688
[PubMed - indexed for MEDLINE]
11.

Fludarabine, treosulfan and etoposide sensitivity and the outcome of hematopoietic stem cell transplantation in childhood acute myeloid leukemia.

Styczynski J, Toporski J, Wysocki M, Debski R, Chybicka A, Boruczkowski D, Wachowiak J, Wojcik B, Kowalczyk J, Gil L, Balwierz W, Matysiak M, Krawczuk-Rybak M, Balcerska A, Sonta-Jakimczyk D.

Anticancer Res. 2007 May-Jun;27(3B):1547-51.

PMID:
17595774
[PubMed - indexed for MEDLINE]
Free Article
12.

Comparison of clofarabine activity in childhood and adult acute leukemia: individual tumor response study.

Styczynski J, Gil L, Derwich K, Wachowiak J, Balwierz W, Badowska W, Krawczuk-Rybak M, Matysiak M, Wieczorek M, Balcerska A, Sonta-Jakimczyk D, Stefaniak J, Kowalczyk J, Urasinski T, Sobol G, Komarnicki M, Wysocki M.

Anticancer Res. 2009 May;29(5):1643-50.

PMID:
19443380
[PubMed - indexed for MEDLINE]
Free Article
13.

Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia.

Gil L, Styczynski J, Dytfeld D, Debski R, Kazmierczak M, Kolodziej B, Rafinska B, Kubicka M, Nowicki A, Komarnicki M, Wysocki M.

Anticancer Res. 2007 Nov-Dec;27(6B):4021-5.

PMID:
18225565
[PubMed - indexed for MEDLINE]
Free Article
14.

Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.

Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB, Dusenbery K, Gamis A, Masterson M, Vik T, Warkentin P, Whitlock JA; Children's Cancer Group Study 2951.

J Clin Oncol. 2003 Aug 1;21(15):2940-7.

PMID:
12885813
[PubMed - indexed for MEDLINE]
15.

Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia.

Styczynski J, Piatkowska M, Jaworska-Posadzy A, Czyzewski K, Kubicka M, Kolodziej B, Kurylo-Rafinska B, Debski R, Pogorzala M, Wysocki M.

Anticancer Res. 2012 Dec;32(12):5495-9.

PMID:
23225457
[PubMed - indexed for MEDLINE]
16.

Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.

Dinndorf PA, Avramis VI, Wiersma S, Krailo MD, Liu-Mares W, Seibel NL, Sato JK, Mosher RB, Kelleher JF, Reaman GH.

J Clin Oncol. 1997 Aug;15(8):2780-5.

PMID:
9256119
[PubMed - indexed for MEDLINE]
17.

Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group.

Carella AM, Carlier P, Pungolino E, Resegotti L, Liso V, Stasi R, Montillo M, Iacopino P, Mirto S, Pagano L, et al.

Leukemia. 1993 Feb;7(2):196-9.

PMID:
8426473
[PubMed - indexed for MEDLINE]
18.

IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.

Yavuz S, Paydas S, Disel U, Sahin B.

Am J Ther. 2006 Sep-Oct;13(5):389-93.

PMID:
16988532
[PubMed - indexed for MEDLINE]
19.

Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia.

den Boer ML, Pieters R, Kazemier KM, Rottier MM, Zwaan CM, Kaspers GJ, Janka-Schaub G, Henze G, Creutzig U, Scheper RJ, Veerman AJ.

Blood. 1998 Mar 15;91(6):2092-8.

PMID:
9490695
[PubMed - indexed for MEDLINE]
Free Article
20.

FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.

Quarello P, Berger M, Rivetti E, Galletto C, Masetti R, Manicone R, Barisone E, Pession A, Fagioli F.

J Pediatr Hematol Oncol. 2012 Apr;34(3):208-16. doi: 10.1097/MPH.0b013e3182427593.

PMID:
22395219
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk